BrightSpring Health Services, Inc. Common Stock
BTSG
$63.80
+0.08%
BrightSpring Health Services is a home and community-based healthcare platform that delivers complementary pharmacy and provider services to complex, high-acuity patients across Medicare, Medicaid, and commercially insured populations, operating through Pharmacy Solutions and Provider Services segments with the pharmacy arm generating the majority of revenue. As one of the largest scaled players in specialty and infusion pharmacy for complex populations, BrightSpring occupies a distinct niche at the intersection of pharmacy distribution and in-home clinical care, a positioning that is difficult to replicate given its national footprint and payer relationships. The current investor narrative centers on the company's rapid growth trajectory, with specialty pharmacy sales up roughly 30% and Q2 2026 revenue rising 23% year-over-year, alongside a debate over the roughly $200 million revenue headwind from Inflation Reduction Act (IRA) drug-pricing provisions that management argues is largely offset by operational efficiencies. A recent strategic divestiture of the ResCare Community Living business to Sevita has sharpened the story around core pharmacy and provider growth, while the stock's strong post-IPO performance and heavy analyst coverage have made it a closely watched name in healthcare services.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$63.80
Related headlines
Investment Opinion: Should I buy BTSG Today?
The synthesized recommendation is a Buy, anchored by the strong analyst consensus (17 analysts, mean rating 1.18) and an average target price of $78.94, implying 31% upside from the current $60.25. The core thesis is that BrightSpring's 23% revenue growth, expanding margins, and dominant position in complex patient pharmacy services will drive earnings growth that justifies the premium valuation, especially as the IRA headwind proves manageable.
Supporting evidence includes: 1) Revenue growth of 23.05% year-over-year in Q2 2026, with specialty pharmacy up 30%; 2) Net margin expansion to 2.24% from 0.90% a year ago, and operating margin improvement to 3.73% from 1.54%; 3) Positive TTM free cash flow of $402.35 million, a 5.3% yield; 4) Attractive PS ratio of 0.59x, near the low end of its historical range, and forward PE of 26.45x that implies 34% earnings growth. The stock also offers 31% upside to the average analyst target, with no recent downgrades.
Key risks that could invalidate the thesis include: 1) The $200 million IRA headwind reducing revenue growth below 15%; 2) Margin compression if operational efficiencies fail to offset pricing pressure; 3) Multiple contraction if the PE reverts to the sector average of low-to-mid 20s. The rating would upgrade to a Strong Buy if the stock breaks above $73.75 resistance with sustained volume, or downgrade to Hold if revenue growth decelerates below 15% or if operating margin fails to hold above 3.5%. Relative to its history and peers, the stock appears undervalued on sales (PS 0.59x vs. historical 0.79x-3.71x) but fairly valued to slightly overvalued on earnings (PE 39.84x vs. sector low-to-mid 20s). The balance of evidence supports a Buy for growth-oriented investors comfortable with volatility.
Sign up to view all
BTSG 12-Month Price Forecast
The forward-looking view is bullish, supported by strong revenue growth, margin expansion, and a robust analyst consensus. However, confidence is medium due to the $200 million IRA headwind, high leverage, and a premium PE multiple that leaves little room for error. The stock's recent 12.72% three-month decline and high beta (1.85) suggest volatility will persist. I would upgrade to high confidence if the company demonstrates sustained margin expansion above 4% operating margin and revenue growth above 20% for two consecutive quarters. I would downgrade to neutral if revenue growth falls below 15% or if operating margin fails to hold above 3.5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $78.94 and implied upside of +23.7% versus the current price.
Average Target
$78.94
0 analysts
Implied Upside
+23.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $90
Analyst target range
Coverage is robust with 17 analysts, and the consensus recommendation is a strong buy with a recommendation mean of 1.18, reflecting near-unanimous bullishness. The average target price of $78.94 implies roughly 31% upside from the current price of $60.25, a substantial gap that suggests analysts see the recent pullback as a buying opportunity rather than a fundamental deterioration. The consensus leans decisively bullish, and the estimated average EPS of $5.45 for the coming year supports the view that earnings growth will drive the stock higher. The target range spans from a low of $70.00 to a high of $90.00, a spread of about 29% that signals moderate but not extreme uncertainty. The high target of $90.00 implies roughly 49% upside and likely assumes successful navigation of the IRA headwind, continued 20%+ revenue growth, and further margin expansion toward mid-single-digit net margins. The low target of $70.00 still represents about 16% upside and likely prices in slower growth, IRA pressure, and stable but unspectacular margins. Institutional ratings show a consistent pattern of reiterations rather than upgrades or downgrades, with BTIG, KeyBanc, Morgan Stanley, Wells Fargo, UBS, B of A, TD Cowen, and Goldman Sachs all maintaining Buy or Overweight ratings through mid-2026, indicating strong conviction and no recent negative revisions. The tight clustering of targets and the absence of downgrades suggest analysts have high confidence in the growth story, though the wide gap between the current price and the average target may also reflect that the stock has not yet re-rated to reflect the improving fundamentals.
Drowning in data?
Find the real signal!
Bulls vs Bears: BTSG Investment Factors
The bull case currently has stronger evidence, driven by 23% revenue growth, expanding margins, and a strong analyst consensus with 31% upside to the average target. However, the bear case highlights significant risks: a $200 million IRA headwind, thin margins, high leverage, and a premium PE multiple that leaves little room for execution missteps. The most important tension is whether BrightSpring can sustain its 23% revenue growth and margin expansion in the face of IRA pricing pressure and a low-margin business model. If the company successfully offsets the IRA headwind and continues to scale profitability, the stock could re-rate toward analyst targets; if growth decelerates or margins stall, the premium valuation could compress sharply.
Bullish
- Revenue growth accelerating at 23% YoY: Q2 2026 revenue of $3.873 billion rose 23.05% year-over-year, up from $3.148 billion in Q2 2025, with specialty pharmacy sales reportedly up 30%. This consistent double-digit expansion demonstrates strong demand for BrightSpring's complex patient services.
- Margin expansion driving profitability: Gross margin expanded to 12.72% in Q2 2026 from 11.91% a year earlier, while operating margin more than doubled to 3.73% from 1.54%. Net income surged to $86.69 million (2.24% net margin) from $28.21 million (0.90% net margin), showing operating leverage.
- Strong analyst consensus with 31% upside: All 17 analysts rate the stock a strong buy (mean 1.18), with an average target price of $78.94 implying 31% upside from $60.25. The low target of $70 still offers 16% upside, and no downgrades have occurred through mid-2026.
- Attractive valuation on sales and forward earnings: The stock trades at just 0.59x trailing sales and 0.95x EV/Sales, near the low end of its historical PS range (0.79x-3.71x). Forward PE of 26.45x represents a 34% compression from trailing 39.84x, reflecting expected earnings growth.
Bearish
- IRA headwind threatens revenue growth: The Inflation Reduction Act drug-pricing provisions create a roughly $200 million revenue headwind, which could pressure the 23% growth rate. While management claims operational efficiencies offset the impact, the net effect on margins remains uncertain.
- Thin margins and high leverage: Net margin of 2.24% and operating margin of 3.73% are razor-thin, leaving little room for error. Debt-to-equity of 1.44 and total debt to capitalization of 53.82% amplify financial risk, especially with interest coverage of only 3.92x.
- Recent momentum breakdown and volatility: The stock is down 12.72% over three months and flat over the past month, with relative strength of -16.06 versus SPY over three months. A beta of 1.85 and max drawdown of -23.62% signal high volatility and potential for further declines.
- Premium PE multiple vulnerable to compression: Trailing PE of 39.84x is a 60-70% premium to typical healthcare services multiples in the low-to-mid 20s. If earnings growth disappoints, the multiple could compress toward sector averages, implying significant downside.
BTSG Technical Analysis
BrightSpring is in a powerful primary uptrend, with the shares up 109.57% over the trailing year versus a 15.01% gain for SPY, a relative strength advantage of 94.56 percentage points. At the current price of $60.25, the stock sits at roughly 72% of its 52-week range (52-week low of $27.11, high of $73.75), meaning it has more than doubled off its lows but remains about 18% below its peak. That positioning suggests a stock in a healthy uptrend that has already absorbed a meaningful correction rather than one pressing against overextended highs, offering a more balanced risk-reward than a pure momentum chase. Recent momentum has cooled materially, however: the shares are down 12.72% over three months and flat over the past month (0.0% change), with relative strength of -16.06 versus SPY over three months and -0.59 over one month. This deceleration follows a sharp single-day drop from $72.88 on July 30 to $59.71 on July 31, a roughly 18% gap that likely reflects an earnings or guidance event, and the stock has since chopped in a $55-$63 range. The divergence between the strong 1-year trend and the negative 3-month trend signals a consolidation or distribution phase, and with a short ratio of 4.65, there is meaningful bearish positioning that could fuel a squeeze if the stock reclaims its highs. Key support sits at the $55-$56 area, which has been tested repeatedly through September, with deeper support at the 52-week low of $27.11; resistance is defined by the July high near $72.88 and the 52-week high of $73.75. A breakout above $73.75 would confirm trend resumption and likely force short covering, while a breakdown below $55 would signal a deeper correction toward the $50 area. With a beta of 1.85, the stock is 85% more volatile than the market, and a maximum drawdown of -23.62% underscores the need for disciplined position sizing and wider stop-losses.
Beta
1.88
1.88x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$27-$74
Price range past year
Annual Return
+124.5%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | +0.9% |
| 3m | -10.9% | +3.4% |
| 6m | +40.7% | +14.4% |
| 1y | +124.5% | +16.2% |
| ytd | +66.1% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
Revenue growth is robust and accelerating, with Q2 2026 revenue of $3.873 billion up 23.05% year-over-year, building on Q1 2026 revenue of $3.614 billion and Q4 2025 revenue of $3.551 billion. The sequential progression from $3.148 billion in Q2 2025 to $3.873 billion in Q2 2026 reflects consistent double-digit expansion, and the segment mix shows Commercial Insurance at $1.113 billion and Medicaid at $436.6 million, with specialty pharmacy sales reportedly up 30%. This trajectory implies a business scaling rapidly through both organic growth and share gains in complex patient populations, though the IRA headwind of roughly $200 million in revenue warrants monitoring for its impact on the growth rate. Profitability is thin but improving, with Q2 2026 net income of $86.69 million and a net margin of 2.24%, up from $28.21 million and 0.90% in Q2 2025. Gross margin of 12.72% in Q2 2026 expanded from 11.91% a year earlier, and operating margin improved to 3.73% from 1.54%, though the trailing gross margin of 11.76% remains low relative to typical healthcare services peers, reflecting the low-margin pharmacy distribution component of the model. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 1.44 and total debt to capitalization of 53.82%, alongside a current ratio of 1.57 and interest coverage of 3.92x. Free cash flow is positive but lumpy, with TTM free cash flow of $402.35 million against a market cap of $7.59 billion, implying a modest FCF yield of about 5.3%, while Q2 2026 free cash flow of just $14.88 million was depressed by a $116.76 million working capital drag and $29.03 million in capex. ROE of 10.17% and ROA of 4.88% are respectable for a leveraged healthcare platform, but the company remains dependent on debt markets and internal cash generation to fund growth, making the trajectory of operating cash flow a key metric to watch.
Quarterly Revenue
$3.9B
2026-06
Revenue YoY Growth
+23.1%
YoY Comparison
Gross Margin
12.7%
Latest Quarter
Free Cash Flow
$402351000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Because BrightSpring is profitable with trailing net income of $86.69 million in the most recent quarter and positive EPS of $0.025, the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 39.84x versus a forward PE of 26.45x, a gap that implies the market expects substantial earnings growth, consistent with analyst EPS estimates of $5.45 for the coming year. The forward PE compression of roughly 34% from trailing to forward levels signals that consensus anticipates earnings to more than double, which is a high bar that places significant execution risk on the stock. On a price-to-sales basis, the stock trades at just 0.59x, which is remarkably low for a company growing revenue at 23%, though this reflects the inherently low-margin nature of pharmacy distribution. Compared to the broader healthcare sector, the trailing PE of 39.84x represents a premium to typical healthcare services multiples in the low-to-mid 20s, a spread of roughly 60-70%, while the PS ratio of 0.59x and EV/Sales of 0.95x sit at a discount to higher-margin healthcare peers. The premium on earnings is arguably justified by the 23% revenue growth and expanding margins, but the low PS ratio highlights that the market is not paying up for the revenue base, suggesting skepticism about margin sustainability. Historically, BrightSpring's PE has ranged from negative territory in 2023 to 53.22x in Q4 2024 and 41.51x in Q2 2026, placing the current 39.84x near the middle-to-lower end of its post-IPO range. The PS ratio of 0.59x is near the low end of its historical band, which ranged from 0.79x to 3.71x, indicating the stock is cheap on sales relative to its own history. This combination of a mid-range PE and a low PS suggests the market is pricing in margin expansion but not revenue multiple expansion, leaving room for re-rating if profitability continues to improve.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 25x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial given BrightSpring's thin margins and high leverage. Net margin of 2.24% and operating margin of 3.73% provide minimal buffer against cost inflation or reimbursement pressure, while debt-to-equity of 1.44 and total debt to capitalization of 53.82% increase sensitivity to interest rates. Interest coverage of 3.92x is adequate but not comfortable, and free cash flow is lumpy—Q2 2026 FCF was only $14.88 million due to a $116.76 million working capital drag. The company's reliance on debt markets to fund growth could become problematic if credit conditions tighten or if operating cash flow fails to improve.
Market and competitive risks stem from the stock's premium valuation and high beta. Trailing PE of 39.84x is a 60-70% premium to healthcare services peers, leaving the stock vulnerable to multiple compression if growth slows. Beta of 1.85 means the stock is 85% more volatile than the market, and the recent 12.72% three-month decline with -16.06 relative strength versus SPY indicates waning momentum. Competitive pressures in specialty pharmacy could erode pricing power, and the $200 million IRA headwind represents a tangible regulatory threat. Additionally, the low PS ratio of 0.59x suggests the market is skeptical about margin sustainability, which could cap upside.
In a worst-case scenario, a combination of IRA-driven revenue declines, margin compression, and multiple contraction could drive the stock toward its 52-week low of $27.11. From the current price of $60.25, that represents a 55% decline. A more realistic bear case might see the stock fall to the analyst low target of $70 (which is above current price) or to the $50 support level, implying a 17% loss. However, given the high beta and historical max drawdown of -23.62%, a 30-40% drawdown from current levels is plausible if growth stalls and the PE compresses to 25x on lower earnings. The key trigger would be a significant earnings miss or a guidance cut due to IRA pressures.
FAQ
The most severe risk is the $200 million IRA revenue headwind, which could reduce growth below 15% and pressure margins. Second, the company operates with thin margins (net margin 2.24%, operating margin 3.73%) and high leverage (debt-to-equity 1.44), leaving little buffer for cost inflation or reimbursement cuts. Third, the stock's high beta (1.85) and recent 12.72% three-month decline indicate significant volatility and momentum risk, with a max drawdown of -23.62%. Fourth, competitive pressures in specialty pharmacy could erode pricing power and slow the 30% growth rate. These risks are ranked from most to least severe, with the IRA headwind being the most immediate threat to the investment thesis.
The 12-month forecast includes three scenarios: a bull case (30% probability) targeting $85-90, a base case (50% probability) targeting $75-80, and a bear case (20% probability) targeting $50-55. The base case is most likely, assuming revenue growth moderates to 18-20%, operating margin improves to 3.8-4.0%, and the IRA headwind is largely offset. The bull case requires sustained 20%+ growth and successful margin expansion, while the bear case assumes growth decelerates below 15% and the PE multiple compresses. The key assumption behind the base case is that management can continue to drive operational efficiencies to offset IRA pricing pressure, keeping earnings growth on track to justify the forward PE of 26.45x.
BTSG presents a mixed valuation picture. On a price-to-sales basis, the stock is undervalued, trading at 0.59x trailing sales versus its historical range of 0.79x to 3.71x, and at a discount to higher-margin healthcare peers. However, on earnings, the trailing PE of 39.84x is a 60-70% premium to typical healthcare services multiples in the low-to-mid 20s. The forward PE of 26.45x implies the market expects earnings to more than double, which is a high bar. The low PS ratio suggests the market is skeptical about margin sustainability, while the premium PE reflects growth expectations. Overall, the stock appears fairly valued to slightly undervalued relative to its own history, but the premium on earnings leaves little room for disappointment.
From a risk/reward perspective, BTSG offers a favorable setup for growth-oriented investors. The stock trades at $60.25, with an average analyst target of $78.94 implying 31% upside, and a low target of $70 still offering 16% upside. The company is growing revenue at 23% year-over-year with expanding margins, and the PS ratio of 0.59x is near historical lows. However, the biggest downside risk is the $200 million IRA headwind, which could slow growth and compress the premium PE multiple. A realistic bear case could see the stock fall to $50-55, a 9-17% decline. It is a good buy for investors who believe management can offset IRA pressures and sustain margin expansion, but position sizing should account for the high beta (1.85) and potential volatility.
BTSG is more suitable for a medium-to-long-term investment horizon (at least 12-18 months) given its growth stage, high volatility, and lack of dividend. The company is still scaling, with revenue growing at 23% and margins expanding, but earnings visibility is limited by the IRA headwind and thin margins. The high beta (1.85) and max drawdown of -23.62% make it risky for short-term trading, though the short ratio of 4.65 could fuel squeezes. A long-term investor can benefit from the secular growth in home-based care and specialty pharmacy, but should be prepared for volatility. A minimum holding period of 12 months is suggested to allow for the resolution of IRA impacts and potential multiple re-rating.
